Rani Therapeutics: ‘We’ve Tested A Dozen Molecules, All Of Them Have Worked’
CEO Talat Imran: ‘I Think We Get An Inbound Partner Interest Every Week At This Point’
Executive Summary
In an exclusive interview with Generics Bulletin, Talat Imran, CEO of oral-dose biologics player Rani Therapeutics, talks adalimumab, partnering opportunities and financing, in the wake of kicking off pre-clinical development of its RT-111 proposed biosimilar to Janssen’s Stelara (ustekinumab) contained in its proprietary RaniPill Go ‘robotic’ capsule.
You may also be interested in...
Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market
United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.
Rani Therapeutics Gets Ball Rolling On Oral Stelara Biosimilar
California-based Rani Therapeutics has provided several key pipeline updates and targets, ahead of plans to accelerate development of its proprietary RaniPill Go ‘robotic’ capsule technology in 2023.
Oral Humira Biosimilar Could Be A Game-Changer, Says Rani CEO
Oral delivery of biosimilars could bring significant benefits for patients as well as offering a key differentiating factor for competing developers, especially in the US adalimumab arena, Rani Therapeutics CEO Talat Imran tells Generics Bulletin.